We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The lead product candidate of the company is AT-001, which is a novel ARI with broad systemic expos... Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The lead product candidate of the company is AT-001, which is a novel ARI with broad systemic exposure and peripheral nerve permeability, developed for the treatment of diabetic cardiomyopathy, or DbCM, a fatal fibrosis of the heart. Show more
- Company completed Late-Cycle review meeting with FDA - FDA no longer intends to hold Advisory Committee meeting - FDA Review of NDA continues to proceed as planned with PDUFA target action...
NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against...
NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November 28, 2024, and EMA decision expected in early Q1...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.5016 | 6.27 | 8 | 8.57 | 7.57 | 1431525 | 8.04273215 | CS |
4 | 3.5816 | 72.7967479675 | 4.92 | 8.9 | 4.55 | 5217803 | 7.8308027 | CS |
12 | 3.1966 | 60.2563619227 | 5.305 | 8.9 | 4.55 | 2494584 | 7.24154632 | CS |
26 | 2.9616 | 53.4584837545 | 5.54 | 8.9 | 3.95 | 1696454 | 6.43760196 | CS |
52 | 6.2016 | 269.634782609 | 2.3 | 9.39 | 1.79 | 1655644 | 5.34097462 | CS |
156 | -8.3784 | -49.63507109 | 16.88 | 19.14 | 0.4995 | 801417 | 4.31791219 | CS |
260 | -1.8384 | -17.7794970986 | 10.34 | 57.39 | 0.4995 | 538093 | 7.12919356 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions